The China-Developed Lung Cancer Drug One Decision From the US Market
On August 5, 2026, Summit Therapeutics — the US partner of Chinese biotech Akeso — reported the updated survival analysis of HARMONi, the global Phase III trial of ivonescimab in EGFR-mutant non-small cell lung cancer (NSCLC). With a June 2026 data cutoff, ivonescimab plus platinum-based chemotherapy reduced the risk of death by 24 percent compared with chemotherapy alone, a hazard ratio of 0.76. The result was identical in the overall intention-to-treat population and in the Europe and North America subgroup — the readout that mattered most, because Western patients had been the reason an earlier analysis fell short of significance. Summit has submitted the updated results to the FDA, which is expected to decide on the biologics license application by November 14, 2026.
Ivonescimab is the first PD-1/VEGF bispecific antibody approved anywhere in the world. China's NMPA approved it in May 2024 for EGFR-mutant advanced NSCLC that had progressed after EGFR-TKI therapy — a full year before any Western regulator took up the file. For international patients weighing lung cancer treatment options, the timeline is the story: the drug is already in routine clinical use in Chinese hospitals, already negotiated into China's national reimbursement drug list, and only now approaching its first Western approval decision.
What the Updated HARMONi Data Show
Ivonescimab in EGFR-mutant NSCLC: the numbers
The trial itself is straightforward in design: 438 patients with EGFR-mutant non-squamous NSCLC who had progressed on a third-generation EGFR inhibitor — osimertinib being the common case — were randomized to ivonescimab plus platinum doublet chemotherapy or placebo plus the same chemotherapy. The dual primary endpoints were progression-free survival and overall survival. The first endpoint was met early: ivonescimab cut the risk of progression or death by 48 percent (HR 0.52), with median PFS of 6.8 versus 4.4 months and an objective response rate of 45 percent versus 34 percent.
Overall survival took longer to mature, and the interim trajectory shows why the updated analysis matters. In the pre-specified primary analysis (April 2025), median OS was 16.8 versus 14.0 months with a hazard ratio of 0.79 — a favorable trend that did not formally reach significance (p = 0.057). The trouble spot was the Western subgroup, whose median follow-up was then only 9.2 months and whose hazard ratio sat at 0.98, effectively no benefit. A September 2025 analysis improved the overall HR to 0.78 with a nominal p of 0.0332, and the Western HR moved to 0.84 as follow-up lengthened to 13.7 months. With the June 2026 cutoff — Western follow-up now 23.2 months, Asian 32.7 months — the hazard ratio settled at 0.76 in both populations. The initially confusing regional gap was, in large part, an artifact of immature follow-up in Western patients.
Safety was stable: no new signals, grade 3 or higher treatment-related adverse events in 50 percent of the combination arm versus 42.2 percent of the control arm, and grade 3 or higher bleeding — the event class that matters most for a VEGF-directed agent — in 0.9 percent of patients on ivonescimab.
Why This Setting Matters — Especially in Asia
EGFR-mutant lung cancer is the poster child for Asian-West differences in oncology. Roughly 40-50 percent of East and Southeast Asian NSCLC patients carry EGFR mutations, versus around 15 percent of Western patients. That prevalence is why the EGFR-mutant, post-TKI population has always been a China-driven clinical question — and why Chinese hospitals treat more of these patients than any other system in the world. The standard sequence is well established: an EGFR inhibitor such as osimertinib first, then, at progression, chemotherapy-based regimens with or without an immunotherapy backbone. Ivonescimab's design attacks both sides of that progression biology at once — blocking PD-1 to reactivate T cells against the tumor while blocking VEGF to starve the blood supply the tumor grows — in a single tetravalent molecule.
The competitive field here is real: the EGFR-mutant, post-TKI space has seen multiple immuno-chemotherapy combinations stumble on survival, which is precisely why the HARMONi readout has been scrutinized for three years. A hazard ratio of 0.76 with consistent benefit across regions is a registration-quality result — the kind of number that changes guidelines, and the reason the FDA is reviewing the file at all.
Beyond Lung Cancer: Bladder Cancer and the ADC Combination Push
The same week's news shows the program expanding beyond NSCLC. Summit has initiated HARMONi-GU1, a global Phase II/III trial of ivonescimab in bladder cancer — the first major extension of the program into a genitourinary indication — and continues to build the lung cancer program around combination strategy. Akeso, for its part, announced on July 27 that the first patient had been dosed in AK138D1-201, a Phase Ib/II study of its next-generation HER3 antibody-drug conjugate, AK138D1, combined with ivonescimab across multiple advanced NSCLC settings — first-line, post-EGFR-TKI, and post-immuno-chemotherapy. The Akeso announcement frames this as an "IO2.0 + ADC2.0" matrix: the approved bispecific as the immune backbone, next-generation ADCs as the payload layer, both built in-house in Guangdong.
None of this is speculative for patients in China. The HER3 ADC is in Phase II, the bladder cancer trial is global, and the combination studies are enrolling — but the commercially available anchor remains ivonescimab itself, which Chinese oncologists have now prescribed for more than two years.
The China Angle: Where Ivonescimab Is Already Routine
The practical gap between China and the rest of the world is the point of interest for this site's readers. In the United States and Europe, ivonescimab is a trial drug today; in China it is a listed medicine with two years of real-world use behind it. Akeso launched the drug commercially in June 2024, and the 2024 national reimbursement negotiation put it on China's National Reimbursement Drug List effective January 2025 — which anchors the price Chinese hospitals charge, including to self-paying international patients. NRDL-negotiated oncology prices in China typically run 60-80 percent below US list prices, so an ivonescimab-based regimen in China costs a fraction of what an equivalent PD-1/PD-L1 plus chemotherapy sequence costs in Singapore, Korea, or Western Europe — the comparison that matters most for the site's main audiences in Southeast Asia, Russia and Central Asia, and the Middle East.
It is also worth noting where the drug came from: Akeso is a Zhongshan, Guangdong company that went from founding in 2012 to two approved bispecific antibodies, with ivonescimab now the anchor of a global Phase III program run by a Nasdaq-listed partner. The 2025 record — 76 innovative drugs approved in China — was the aggregate number; ivonescimab's FDA timeline is the specific instance of the same pipeline maturing. Chinese hospitals have the drug, the experience, and the patient volume.
What International Patients Can Access Today
For an international patient with EGFR-mutant NSCLC, the realistic options in China are:
- Commercial treatment — ivonescimab-based regimens are available now at major lung cancer centers, including Shanghai Chest Hospital, Zhongshan Hospital Fudan University, and Guangdong Provincial People's Hospital. Treatment plans and cost estimates come from the hospital's international department; our best cancer hospitals guide covers how to choose, and the cancer treatment cost guide explains the price picture.
- Trial participation — HARMONi program sites and the AK138D1 combination studies enroll through Chinese centers; enrollment is arranged through the same international departments.
- The sequencing decision — for patients who have not yet failed an EGFR inhibitor, the first-line question (TKI alone versus TKI-plus combinations) is a live medical decision, and second opinions at Chinese centers are inexpensive relative to the same consultation in Singapore or Hong Kong.
The cancer treatment in China guide walks through the full pathway, and our visa guide covers entry routes, including visa-free transit and Hainan. For patients weighing whether to wait for the FDA decision before committing to treatment abroad: the drug will not be cheaper in the United States than in China, and the November 14 date does not change what is already available at Chinese hospitals today.
The China-Specific Extra: Integrated Supportive Care
Chinese lung cancer centers add a layer most Western hospitals do not: integrated Chinese-Western medicine (中西医结合) running alongside the oncology protocol. During an ivonescimab-plus-chemo course, Chinese teams routinely add acupuncture for chemotherapy-induced nausea and peripheral neuropathy, herbal formulas to manage fatigue and appetite loss, and post-infusion recovery protocols — adjunctive symptom management delivered inside the same hospital by the same care team, not alternative treatment standing in for the regimen. The nausea evidence is among the best-documented in acupuncture research, and for a patient facing months of platinum-based therapy the difference in day-to-day tolerance is measurable. Our integrated Chinese-Western medicine guide and the TCM in China guide explain how these services are booked and what they cost.
What to Watch Next
Three dates and data points matter over the next six months: the FDA decision on or before November 14, 2026; the full June 2026 HARMONi survival data — medians, confidence intervals, and p-values — which Summit says will be presented at a future medical congress; and the first readouts from the HARMONi-GU1 bladder cancer program. For the broader China pipeline picture, the record 2025 approval year and the senaparib licensing deal show the same pattern: China-first approval, world-class trial data, then global expansion. Ivonescimab is simply the furthest along.
The bottom line: a Chinese bispecific that has been treating EGFR-mutant lung cancer patients in China since 2024 now has registration-quality survival data — HR 0.76, a 24 percent reduction in death risk, consistent across regions — and an FDA decision date of November 14, 2026. International patients who need this drug today can get it at Chinese cancer centers at negotiated prices, with integrated TCM supportive care, while the rest of the world waits on regulators. Trial and commercial tracking for the program is available on clinicaltrials.gov and the Akeso newsroom.